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INTRODUCTION:  We  describe  a novel  treatment  of  mucocutaneous  peristomal  junction  breakdown  in a
patient with  severe  eczema  using aerosol  steroids,  where  conventional  methods  failed  to  achieve  healing.
PRESENTATION  OF CASE:  Observation  and  photographic  evidence  showing  resolution  of  severe  peristomal
eczema  in a patient,  in  whom  systemic  steroids  were  contraindicated,  using  a topical  aerosol  steroid.  We
found complete  resolution  of  peristomal  eczema  and  symptoms  within  four  weeks.toma
eristomal
czema
nhaled steroids
erosol steroids
DISCUSSION:  Topical  aerosol  steroids  are  better  tolerated  than  alcohol  based  steroid  preparations,  achieve
improved  stoma  appliance  adherence  in  comparison  to oil based  steroid  preparations  and  reduce  systemic
side  effects  in  comparison  to  systemic  oral  steroids.
CONCLUSION: Aerosol  steroids  appear  to be a  safe  and  effective  way  to  treat  refractory  peristomal  eczema
and may  be of use  in  other  peristomal  inﬂammatory  conditions  including  contact  dermatitis.
© 2014  The  Authors.  Published  by Elsevier  Ltd.  on behalf  of  Surgical  Associates  Ltd.  This  is  an  open
access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/3.0/).. Introduction
Almost 100,000 people in the UK have a surgically made stoma.1
eristomal skin integrity is vital for a stoma appliance adherence.
ucocutaneous breakdown affects the base plate’s ability to attach
roperly to the skin and may  result in leakage. This can be debili-
ating for patients and result in social isolation.2
Little has been published on the prevalence, prevention or
anagement of stoma skin problems and even less on speciﬁc
re-existing dermatological diseases and stomas. Peristomal skin
roblems are thought to be common with some studies repor-
ing frequencies of up to 60%.3 In a postal questionnaire study by
yon et al.1 psoriasis, seborrhoeic dermatitis and eczema together
ccounted for 20% of the peristomal skin problems encountered.
The mainstay of treatment for patients with eczema affecting
eristomal skin is topical steroids such as betamethasone valer-
te (0.1%) aqueous lotion applied to peristomal skin with each bag
hange for two weeks.1,4–7 Systemic steroid therapy may  be indi-
ated if disease is widespread or not responding to topical steroids.
Topical therapy can be suboptimal and some patients may  have
ontraindications to systemic therapy. We  describe and present novel technique in a patient whose severe peristomal eczema
esponded to aerosol steroids after other treatments had failed.
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210-2612/© 2014 The Authors. Published by Elsevier Ltd. on behalf of Surgical A
http://creativecommons.org/licenses/by-nc-nd/3.0/).2. Presentation of case
A 52-year-old man  was presented with an obstructing non-
metastatic anal squamous cell carcinoma and required a trephine
defunctioning loop colostomy positioned in the left iliac fossa.
Following fashioning of his colostomy he developed a gener-
alised exacerbation of eczema with widespread erythematous skin
and multiple excoriations consistent with infected eczema. This
resulted in breakdown of the mucocutaneous junction of the stoma
due to eczema. There was no leakage of the appliance to sug-
gest contact dermatitis at this stage, conﬁrmed after Dermatology
advice was  sought. Systemic steroids were absolutely contraindi-
cated due to an unrelated episode of septic arthritis of the elbow
joint during the admission, requiring surgical drainage and par-
enteral antibiotics.
Despite response of the systemic eczema to appropriate medical
therapy (including antibiotics and topical steroid ointment), the
peristomal eczema deteriorated in our patient. (Fig. 1) The mainstay
of treatment at this time was topical steroids. The oil based steroid
ointment, however, resulted in poor stoma appliance adherence
with multiple stoma bag leakages, thus driving the cycle of further
skin irritation.
Other corticosteroid preparations, including a water miscible
scalp lotion (betnovate valerate 0.1%) were trialled. It is thought
that water miscible scalp lotions do not impair adhesion of the
stoma pouch to clean dry skin. Unfortunately these preparations
were poorly tolerated, as the alcohol content resulted in severe
discomfort when applied to broken skin.
ssociates Ltd. This is an open access article under the CC BY-NC-ND license
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Fig. 1. Mucocutaneous peristomal breakdown due to eczema after conventional
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to topical and aerosol steroids which are absorbed directly into
the systemic circulation via the skin. All preparations are excreted
in urine via the kidneys as sulphate and glucuronide conjugates.
Table 1
Advantages and disadvantages of different types of steroids used to treat peristomal
eczema.
Advantages Disadvantages
Oil based topical
steroids (e.g.
clobetasol
• Reduced systemic side
effects
• Poor bag adherenceopical steroid treatment.
With failure of conventional management of mucocutaneous
toma breakdown in our patient with infected eczema, a trial of
eclometasone dipropionate aerosol inhaler was introduced and
igniﬁcant improvement was seen within a week (Fig. 2). Two  puffs
f the aerosol were applied topically to the peristomal area at each
toma bag change. Bag leakage and irritation were reduced, patient
atisfaction and pain improved and application of the inhaler was
elt to be more convenient than other methods trialled. Four weeks
fter commencing topical aerosol steroids, complete healing of the
eristomal ulceration was seen. At eight month follow up this good
esponse was sustained without the need for any further steroid use
Fig. 3).
. Discussion
In comparison to other methods of treating peristomal eczema
Table 1), aerosol steroids are a quick, easy to apply method that
educes both the systemic side effects of oral steroids and the prob-
ems of stoma bag leakage seen with oil based preparations. The
erosol steroid is well tolerated in patients with broken peristomal
kin unlike an alcohol based preparation.
To date there has only been one case report in the literature from
oland and Brooks8 in 2012 describing the use of aerosol steroids
o treat peristomal inﬂammation secondary to contact dermatitis
n contrast to peristomal eczema.
ig. 2. Peristomal area of colostomy one week after commencing topical beclometa-
one dipropionate aerosol treatment.Fig. 3. Long-term follow-up of colostomy at eight months showing complete reso-
lution.
The advantages and disadvantages of different types of steroids
used to treat peristomal eczema are listed in Table 1.
There are few complications of aerosol steroids in the doses
used, however, the same complications should be expected of pro-
longed exposure to any steroid. Thus refractory treatment greater
than four weeks should prompt the clinician to rethink the diagno-
sis.
Oral corticosteroids are rapidly absorbed by the gastrointestinal
tract and subject to ﬁrst pass metabolism in the liver in contrastpropionate)
• Good compliance with
broken skin
• Lotion needs to dry
before applying bag
Water based topical
steroids (e.g.
betamethasone
valerate)
• Reduced systemic side
effects
• Irritation on repeated
application
•  Acceptable bag
adherence
• Discomfort due to
alcohol content
• Lotion needs to dry
before applying bag
• ‘Off licence’
Aerosol steroids (e.g.
beclometasone
dipropionate)
• Reduced systemic side
effects
• ‘Off licence’
•  Good bag adherence
• Good compliance with
broken skin
• ‘Cooling’ effect on skin
• Quick dry, no waiting
before applying bag
Systemic steroids (e.g.
prednisolone)
• Treats systemic eczema • Risk of systemic side
effects
•  No local irritation • Relative
contraindication in sepsis
• No bag adherence
issues
• Reduced efﬁcacy for
local symptoms
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opical and aerosol steroids are associated with lower toxicity than
ystemic steroids.9
. Conclusion
In conclusion aerosol steroids can successfully treat peristomal
kin breakdown and ulceration in a patient due to severe eczema.
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